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FMD as a measure of endothelial function after six months ofEffect of fluvastatin on endothelium-dependent brachial artery
treatment. In contrast, FLU does not have a beneficial effectvasodilation in patients after renal transplantation.
on brachial artery DC.Background. Hypercholesterolemia may affect both endothe-
lial function and arterial distensibility (DC). Renal transplant
recipients (NTX) exhibit advanced structural and functional
alterations of arterial vessel walls. The aim of this double-
Cardiovascular disease is a major cause of morbidityblind, randomized trial was to evaluate the effects of fluvastatin
and mortality in patients after renal transplantation and(FLU) on brachial artery flow-mediated vasodilation (FMD)
and DC in hypercholesterolemic NTX. one of the most important determinants of long-term out-
Methods. Eighteen NTX received FLU 40 mg/day and 18 come of transplantation [1–3]. The functional and struc-
NTX placebo (PLA). Before and after six months of treatment, tural alterations of large arteries leading to cardiovascu-the brachial artery diameter and DC at rest were measured by
lar disease begin in the early stages of renal disease, anda Doppler frequency analysis in the M mode, and then changes
in diameter during reactive hyperemia (to assess endothelial- by the time of renal transplantation, arterial disease is
dependent FMD) and after 400 mg sublingual nitroglycerin (to already advanced in the majority of even clinically
assess endothelium-independent vasodilation—NMD). asymptomatic renal transplant recipients [1, 4]. The ath-
Results. FLU, but not PLA, treatment resulted in significant
erosclerotic process covers a spectrum extending fromdecreases in total (from 288 6 10 to 239 6 8 mg/dL, P , 0.05)
endothelial dysfunction to structural alterations of theand low-density lipoprotein cholesterol (from 182 6 779 to
138 6 8 mg/dL, P , 0.05). Blood pressure did not differ be- arterial wall with eventually occlusion of the artery lead-
tween FLU- and PLA-treated patients and was not affected ing to ischemia and infarction [1]. Endothelial dysfunc-
by either treatment. Also, the brachial artery baseline diameter tion and disturbed cushioning function of large arterieswas not different between groups and was not affected by
are generally observed after renal transplantation [5],FLU or PLA. Brachial artery flow at rest and during reactive
but are also found in patients without clinical symptomshyperemia as measured by pulsed Doppler did not differ be-
tween groups. Brachial artery FMD increased with FLU from of cardiovascular disease and are associated with sub-
0.23 6 0.08 to 0.54 6 0.08 mm (P , 0.05), whereas PLA did stantial structural vessel wall alterations such as intima
not alter FMD (0.22 6 0.07 vs. 0.14 6 0.05 mm at baseline media thickening and atherosclerotic plaque formationand after six months of PLA treatment, respectively, P 5 NS).
[4]. Hypercholesterolemia is observed in the majority ofIn contrast, NMD did not change significantly with either treat-
patients after renal transplantation [6] and may be a ma-ment (0.76 6 0.13 vs. 0.83 6 0.15 mm at baseline and after 6
months of FLU treatment, respectively, P 5 NS, and 0.64 6 jor contributor to the previously mentioned vessel wall
0.09 vs. 0.66 6 0.10 mm at baseline and after 6 months of PLA alterations [7]. In hypercholesterolemic humans with-
treatment, respectively, P 5 NS). Also, brachial artery DC was
out cardiovascular disease, endothelial dysfunction isnot altered by FLU (6.4 6 1.0 vs. 5.8 6 0.6 3 1023/kPa, P 5
improved by treatment with 3-hydroxy-3-methylglutarylNS) or PLA treatment (5.8 6 0.6 vs. 6.8 6 0.8 3 1023/kPa,
P 5 NS). coenzyme A (HMG-CoA) reductase inhibitors [8–10].
Conclusions. In hypercholesterolemic NTX, the HMG-CoA Also, in patients with documented coronary artery disease,
reductase inhibitor FLU significantly improves brachial artery HMG-CoA reductase inhibitors may have beneficial ef-
fects on endothelial function [11]. Finally, HMG-CoA
reductase inhibitor treatment in patients with familiarKey words: hypercholesterolemia, HMG-CoA reductase inhibitor,
cholesterol, endothelial cells, cardiovascular disease. hypercholesterolemia may improve elastic properties of
large arteries [12]. Until the present, there are no studies
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and after renal transplantation. The present study was with dinner. Patients were studied twice: at entry into the
study and after the six-month observation period.therefore designed to test the hypothesis that the HMG-
CoA reductase inhibitor fluvastatin (FLU) can improve
Measurementsendothelial function and arterial distensibility in patients
after renal transplantation. In the present prospective, All studies were performed between 8 and 12 a.m.
double-blind, randomized study, flow-mediated vasodila- Twelve to 14 hours had elapsed between the measure-
tion (FMD) and distensibility of the brachial artery were ments and previous intake of cyclosporine or antihyper-
measured by high-resolution ultrasound and Doppler fre- tensive drugs. Only patients without an arteriovenous
quency analysis of vessel wall movements in M mode as fistula or previous vascular surgery on the right arm
indices of endothelial function and mechanical vessel were included into study. Following blood sampling and
wall properties, respectively, in placebo and FLU-treated routine clinical examination, blood pressure, distensi-
renal transplant recipients. bility (DC), as well as flow-mediated and nitroglycerin-
mediated vasodilation of the brachial artery were studied
as described earlier [5], after a rest of at least 15 minutes
METHODS in a supine position. In brief, brachial artery blood pres-
We performed a randomized, prospective, double-blind, sure was measured using an automatic sphygmomanom-
placebo-controlled trial that was approved by the ethics eter, and heart rate was determined using an echocardio-
committee of the University of Mu¨nster School of Medi- gram monitor. After blood pressure measurements, the
cine. All patients gave their written informed consent. brachial artery of the right arm was visualized in a longi-
Eligible patients were between 18 and 60 years of age tudinal section 2 to 6 cm above the elbow using a 7.5 MHz
and had received a kidney from a cadaveric donor at linear array transducer and a standard Toshiba ultra-
least six months earlier. At the time of transplantation, sound system. The brachial artery was displayed in B
all patients had been instructed to follow a reduced cho- and M modes. Vessel diameter was then analyzed using
lesterol (American Heart Association step 1 diet). Renal a multigate pulsed Doppler system. Low-frequency Dopp-
transplant function was stable, and the serum creatinine ler signals originating from the sample volumes coincid-
level was below 2.5 mg/dL in all patients at entry into study. ing with the arterior and posterior vessel walls were
Patients with serum cholesterol levels above 200 mg/dL processed. The positions of sample volumes were contin-
and below 350 mg/dL were included into study. Subjects uously adjusted according to the displacement of the
with prior HMG-CoA reductase inhibitor or other anti- wall. Using the echocardiogram trigger, the end-diastolic
lipidemic medication were excluded. Blood pressure was diameter and distention (diastolic–systolic diameter
controlled in hypertensive renal transplant recipients by change) of the brachial artery were measured. Coeffi-
antihypertensive drugs, and blood pressure levels were cient of variation was 4.5% for the end-diastolic diameter
below 160 mm Hg systolic and 90 mm Hg diastolic in (N 5 26) and 9.6 6 1.6% (N 5 26) for the relative
all patients at randomization. Patients with clinical evi- distention of the brachial artery. After two measure-
dence of cardiovascular disease or diabetes mellitus were ments of end-diastolic diameter at baseline were taken,
excluded. An immunosuppressive drug regimen with a cuff placed on the forearm was inflated at 300 mm Hg
cyclosporine A and prednisolone (5 to 10 mg/day) was during four minutes. During the last minute of cuff infla-
used. Cyclosporine whole-blood trough concentrations tion and at 1, 3, 5, 7, and 10 minutes after cuff release,
(measured by high-performance liquid chromatography) further measurements of brachial end-diastolic diameter
were maintained at 75 to 150 mg/L by dose adjustment. were taken. Brachial artery flow at baseline and during
A total of 40 patients was included into the study. the initial 15 seconds of reactive hyperemia was esti-
mated using a pulsed Doppler. Eleven minutes after cuffCauses of renal failure were chronic glomerulonephri-
release and return of the brachial artery diameter totis in 21 cases, chronic interstitial nephritis in 7 cases,
baseline values, 400 mg of glycerol trinitrate were admin-glomerulosclerosis in 2 cases, polycystic renal disease in
istered sublingually, and further scans of the brachial4 cases, hydronephrosis in 1 case, Alport’s disease in
artery were taken after one, three, and five minutes.1 case, and unknown in 4 cases. Antihypertensive ther-
Ultrasound measurements were taken by two investiga-apy consisted of b blockers (21 patients), calcium antago-
tors (M.H. and M.B.); however, in each patient, bothnists (25 patients), angiotensin-converting enzyme (ACE)
measurements were taken by the same investigator.inhibitors (19 patients), a blockers (4 patients), and loop
diuretics (21 patients). Antihypertensive treatment was
Analysesnot changed in any patient during the six-month observa-
tion period. From the end-diastolic diameter (d), the relative sys-
tolic increase of vessel diameter (relative distention 5Patients were randomly assigned to six months of treat-
ment with FLU 40 mg or matching PLA taken once daily Dd 3 d21) and from the SBP and diastolic blood pressure
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Table 1. Demographic data when compared with the PLA-treated group (Table 2).
As expected, there was a significant decrease of totalFLU PLA
serum cholesterol and LDL cholesterol level in FLU-(N518) (N518) P
treated patients when compared with PLA-treated pa-Age years 5062 4763 NS
tients (P , 0.001; Table 2). In the PLA-treated group,Time after transplantation years 4.960.7 4.060.8 NS
Patients on ACE inhibitor total serum cholesterol and LDL cholesterol level re-
therapy 9 8 NS mained unchanged after six months when compared withSmoker/nonsmoker 3/15 5/13 NS
baseline levels. High-density lipoprotein (HDL) choles-Gender male/female 13/5 13/5 NS
Body mass index kg/m2 2661 2361 NS terol levels at entry and after six months of therapy did
Displayed are age, time after transplantation, smoking habits, gender and not differ between both study groups. There was no
body mass index of patients treated with fluvastatin (FLU) or placebo (PLA). significant difference of triglyceride levels at baselineData are means 6 SEM.
between both study groups, and therapy with either FLU
or PLA did not significantly alter triglyceride levels.
The results of blood pressure measurements and the
(DBP), arterial wall DC was calculated (DC coefficient vessel parameters are shown in Table 3 and Figures 1
DC 5 2 Dd 3 d21 3 (SBP 2 DBP)21 [1023 kPa]). and 2. Blood pressure at baseline was not significantly
Flow-mediated vasodilation was calculated as the max- different between FLU- and PLA-treated patients and
remained unchanged after six months of therapy. Theimum increase in brachial artery end-diastolic diameter
same was true for pulse pressure and heart rate.during reactive hyperemia. Nitroglycerine-mediated va-
The end-diastolic diameter of the brachial artery atsodilation was accordingly calculated as the maximum
baseline was not significantly different in FLU-treatedincrease in brachial artery end-diastolic diameter after
patients when compared with PLA-treated patients.sublingual glycerol trinitrate.
There was no significant effect of either treatment onData were expressed as mean 6 SEM. A statistical
end-diastolic diameter of the brachial artery. Brachialcomparison between the FLU-treated and PLA-treated
artery distention and DC coefficients were also compara-groups was carried out using the Student t test for contin-
ble in both study groups at baseline and not significantlyuous variables and the chi-square test for qualitative
influenced by either treatment.variables. To test the effects of a sixth-month therapy
Flow-mediated vasodilation at baseline was similar inwith FLU or PLA, repeated measures of analysis of vari-
both study groups. However, FMD of the brachial arteryance with adjustment for covariates (ANCOVA) was used.
significantly improved after six months of treatment withWithin- and between-group comparisons were made
FLU. In contrast, FMD of the brachial artery did notwith post hoc tests (planned contrasts).
change from baseline values after six months of PLA
therapy. Improved FMD in FLU-treated patients was not
RESULTS related to changes in brachial artery blood flow. Resting
brachial blood flow at baseline and after six months ofFour of the 40 included patients dropped out during
therapy was not different between both study groups.follow-up, and a second measurement of vessel wall prop-
Peak blood flow after release of forearm occlusion waserties could not be obtained. One patient (PLA group)
also comparable between both study groups at baselinedeveloped bronchial carcinoma. One patient (FLU group)
and after six months of therapy. The effect of FLU as com-developed myalgias, and two patients (one in each
pared with PLA on brachial artery FMD also remainedgroup) withdrew consent. The following analysis, there-
statistically significant after adjustment for brachial ar-fore, is confined to the remaining 36 patients available
tery diameter (P , 0.05) as analyzed by ANCOVA.for according-to-protocol analysis.
Endothelium-independent nitroglycerin-induced vaso-Baseline characteristics of the two groups are shown
dilation was similar in FLU-treated and in PLA-treatedin Table 1. There were no significant differences between
patients at baseline and after six months of therapy.FLU- and PLA-treated patients with respect to age, time
Changes in brachial artery flow-mediated dilatationafter transplantation, number of smokers, gender, and
were not related to changes in serum cholesterol levelsbody mass index.
in either group (Fig. 3) and were also not related to
Biochemical parameters at entry and after six months
changes in LDL cholesterol levels after FLU or PLA
of therapy are shown in Table 2. Cyclosporine and serum treatment (r 5 0.29 for the FLU group and r 5 0.16 for
creatinine levels at entry and after six months were com- the PLA group, both P 5 NS).
parable in the FLU- and the PLA-treated groups (Table 2).
The same was true for glucose, bilirubin levels, and cre-
DISCUSSIONatine kinase activity. Total serum cholesterol and low-
density lipoprotein (LDL) cholesterol levels at entry were The present randomized, double-blind, PLA-controlled
study shows that six months of therapy with the HMG-not significantly different in the group treated with FLU
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Table 2. Biochemical data
FLU (N518) PLA (N518)
Time months 0 6 0 6 P
Cyclosporine ng/mL 9169 9767 94612 9468 NS
Creatinine mg/dL 1.460.1 1.560.1 1.360.1 1.360.1 NS
Glucose mg/dL 9163 9663 9264 8763 NS
Bilirubin mg/dL 0.760.1 0.760.1 0.960.1 0.860.1 NS
CK U/L 3864 4666 3964 4566 NS
Cholesterol mg/dL 28868 23969 a 26667 26769 ,0.001
HDL cholesterol mg/dL 6765 7268 6364 6768 NS
LDL cholesterol mg/dL 18269 13868 a 17367 16669 ,0.001
Triglycerides mg/dL 182624 163625 161615 169614 NS
Values are shown for cyclosporine whole blood trough levels, serum concentrations of creatinine, glucose, bilirubin, creatine kinase (CK), total cholesterol, high
(HDL) and low (LDH) lipoprotein, and triglycerides at baseline and after 6 months of treatment with fluvastatin (FLU) or placebo (PLA). Data are mean 6 SEM.
P values are for group 3 time interaction.
a P , 0.05 versus baseline value
Table 3. Hemodynamic and ultrasound measurements at baseline and after six months
FLU (N518) PLA (N518)
0 6 0 6 P
Blood pressure mm Hg
Systolic 13864 13964 13364 13664 NS
Diastolic 8363 8262 8363 8362 NS
Pulse pressure mm Hg 5563 57631 5062 5263 NS
Heart rate min21 6964 7064 6762 6462 NS
BA diameter mm 4.560.2 4.460.1 4.060.2 4.060.2 NS
BA relative distention % 2.460.5 2.060.2 1.960.2 2.360.3 NS
BA baseline flow mL/min 109614 121612 113616 111612 NS
BA peak flow mL/min 571660 638686 527654 608645 NS
Systolic and diastolic blood pressure, pulse pressure, heart rate, brachial artery (BA) end-diastolic diameter, relative distention, baseline blood flow and peak flow
during reactive hyperemia, at baseline and after 6 months of treatment with fluvastatin (FLU) or placebo (PLA). Data are mean 6 SEM. P values are for group 3
time interaction.
Fig. 1. Displayed are flow-mediated (FMD, left panel) and nitroglycer-
ine-mediated vasodilation (NMD, right panel) of the brachial artery at
baseline and after six months of treatment with fluvastatin (FLU; j) Fig. 2. Brachial artery distensibility coefficient (DC) at baseline and
after six months of fluvastatin treatment (FLU; j) or placebo treatmentor placebo (PLA; h). Data are mean 6 SEM. *P , 0.01 vs. baseline
and P , 0.05 for group 3 time interaction. (PLA; h). Data are mean 6 SEM.
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reductase inhibitor in patients with end-stage renal dis-
ease. Since there is a close correlation between endothe-
lial-mediated vasodilation of peripheral and coronary ar-
teries [16], our finding of improved endothelial-mediated
brachial artery vasodilation in renal transplant patients
suggests a beneficial effect of FLU treatment on the
excess cardiovascular morbidity and mortality in this pa-
tient group [3]. Prospective studies investigating this is-
sue are in progress (for example, ALERT study), how-
ever, results are not available yet.
The observed improvement of endothelial function in
renal transplant patients with FLU could also relate to
improved graft survival [17]. Katznelson and Kobashi-
gawa observed a decreased incidence of acute rejections
in renal transplant patients treated with pravastatin,
which was accompanied by an inhibition of cytotoxic
killer cell activity [18]. It has recently been shown that
FLU inhibits the expression of adhesion molecules in
human monocyte cell lines [19], which may be of impor-
tance for both immunologic processes in allograft rejec-
tion and progression of atherosclerotic lesions. We didFig. 3. Change in brachial artery flow-mediated vasodilation (FMD)
plotted against change in total serum cholesterol after six months of not observe any effect of FLU on graft function or on
treatment with fluvastatin (FLU; j) or placebo (PLA; s). Neither in the incidence of acute rejection. This may be explainedFLU- nor in PLA-treated patients was there a significant correlation
by the selection of patients at least six months afterbetween the change in serum cholesterol and the change in FMD (r 5
0.29, P 5 NS for FLU, and r 5 0.16, P 5 NS for PLA). transplantation who had excellent graft function and by
the relatively short observation period.
We did not observe a correlation between the reduc-
tion in serum total cholesterol or LDL cholesterol con-CoA reductase inhibitor FLU can significantly improve
centrations and the achieved increase in brachial arteryendothelial function in patients after renal transplanta-
flow-mediated dilation. This could indicate a cholesterol-
tion. FMD of the brachial artery significantly improved
independent effect of FLU on endothelial function in
with FLU when compared with PLA treatment. The data
renal transplant recipients [15]. In patients with coronary
of the present study therefore suggest that endothelial artery disease, Jarvisalo et al found brachial artery flow-
dysfunction is reversible in patients after renal trans- mediated dilation to be significantly better in patients
plantation despite substantial structural wall alterations on HMG-CoA reductase inhibitor medication than in
of large arteries, which often are found in these patients patients without HMG-CoA reductase inhibitor therapy,
even in the absence of clinical evidence of cardiovascular despite similar cholesterol levels. The effect on FMD
disease [4]. In contrast, FLU failed to improve mechani- was dose dependent [11]. This could be explained by the
cal wall properties of the brachial artery in renal trans- observation of Laufs et al, who reported a direct up-reg-
plant patients. ulation of endothelial nitric oxide synthase by HMG-CoA
Several studies have shown convincingly that already reductase inhibitors [20]. Recently, the cellular uptake
short-term HMG-CoA reductase inhibitor therapy can mechanism for FLU in endothelial cells of the human
improve endothelial dysfunction in patients with hyper- aorta could be characterized suggesting that also FLU
cholesterolemia free of cardiovascular disease or diabe- may have a direct effect on the expression of endothelial
tes mellitus. This has been shown for the forearm vascu- nitric oxide synthase [21].
lar bed [8, 9] as well as for the coronary vessels [13]. Also, Recent observations suggest that an altered expression
in patients with coronary artery disease, recent observa- of angiotensin II type 1 (AT1) receptors may contribute
tions indicate an improvement of endothelial dependent to the improved endothelial function with statin therapy
vasodilation by HMG-CoA reductase inhibitors [11, 14]. [22]. In the present study, patients receiving FLU and
Improvement of endothelial dysfunction is suggested to patients receiving PLA did not differ significantly in their
be a major factor that explains the success of HMG- antihypertensivie medication, particularly not in angio-
CoA reductase inhibitors in the primary and secondary tensin-converting enzyme inhibitor use. Antihyperten-
prevention of cardiovascular disease [15]. To our knowl- sive medication was not changed in any of the patients
edge, the current study is the first report of improvement during the six months of follow-up.
It has been shown that apart from its effects on endo-of endothelial dependent vasodilation by an HMG-CoA
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thelial function hypercholesterolemia also affects me- this is the first report demonstrating improved endothe-
lial function with HMG-CoA reductase inhibitor treat-chanical vessel wall properties of large [23] and medium-
sized arteries [24]. In contrast to the beneficial effects ment in end-stage renal disease. This is an important find-
ing since renal allograft recipients even without clinicalof FLU on brachial artery FMD, we did not observe an
improvement of brachial artery distensibility with FLU. evidence of cardiovascular disease already exhibit sub-
stantial structural alterations of large arteries, which differIt has to be noted that fewer atherosclerotic lesions are
found in the brachial artery than in large elastic-type from those observed in patients with hypercholesterol-
emia [1], and this finding may be of prognostic relevance.arteries [25, 26] and that brachial artery elastic wall prop-
erties are largely determined by blood pressure [27]. In contrast, FLU did not improve elastic properties of the
brachial artery in renal allograft recipients.Therefore, FLU treatment could have resulted in im-
proved DC of elastic type arteries, for example, the com-
mon carotid artery, which is prone to atherosclerosis ACKNOWLEDGMENTS
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period of six months was too short to observe improve-
ments in large artery DC with FLU. In support of this
APPENDIXhypothesis, Giannattasio et al observed an improvement
of radial artery compliance in seven patients with familial Abbreviations used in this article are: ACE, angiotensin-converting
enzyme; AT1, angiotensin II type 1 (receptor); CK, creatine kinase; DBP,hypercholesterolemia not after 6 months, but only after
diastolic blood pressure; DC, distensibility coefficient; FLU, fluvastatin;
24 months of therapy with simvastatin [12]. FMD, flow-mediated vasodilation; HMG-CoA, 3-hydroxy-3-methyl-
glutaryl coenzyme A; HPLC, high-pressure liquid chromatography;Despite the success of HMG-CoA reductase inhibitors
LDL, low-density lipoprotein; NTX, renal transplant recipients; PLA,with respect to primary and secondary prevention of car-
placebo; SBP, systolic blood pressure.
diovascular events in the general population, these drugs
are used with great caution in renal transplant patients.
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